These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35164129)

  • 1. Newly Emerging Strategies in Antiviral Drug Discovery: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Anniversary.
    Xu S; Ding D; Zhang X; Sun L; Kang D; Huang B; Liu X; Zhan P
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35164129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday.
    Li G; Yue T; Zhang P; Gu W; Gao LJ; Tan L
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33572409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq.
    Li G; Xu M; Yue T; Gu W; Tan L
    Biochem Pharmacol; 2021 Mar; 185():114485. PubMed ID: 33617841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The urgent need for pan-antiviral agents: from multitarget discovery to multiscale design.
    V Kleandrova V; Speck-Planche A
    Future Med Chem; 2021 Jan; 13(1):5-8. PubMed ID: 33225723
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19: A Defining Moment for Clinical Pharmacology?
    van der Graaf PH; Giacomini KM
    Clin Pharmacol Ther; 2020 Jul; 108(1):11-15. PubMed ID: 32350861
    [No Abstract]   [Full Text] [Related]  

  • 6. Machine learning techniques applied to the drug design and discovery of new antivirals: a brief look over the past decade.
    Serafim MSM; Dos Santos Júnior VS; Gertrudes JC; Maltarollo VG; Honorio KM
    Expert Opin Drug Discov; 2021 Sep; 16(9):961-975. PubMed ID: 33957833
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug Repurposing for Viral Infectious Diseases: How Far Are We?
    Mercorelli B; Palù G; Loregian A
    Trends Microbiol; 2018 Oct; 26(10):865-876. PubMed ID: 29759926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial overview: Engineering for viral resistance.
    von Brunn A
    Curr Opin Virol; 2015 Oct; 14():v-vii. PubMed ID: 26320757
    [No Abstract]   [Full Text] [Related]  

  • 9. Intervention strategies for emerging viruses: use of antivirals.
    Debing Y; Jochmans D; Neyts J
    Curr Opin Virol; 2013 Apr; 3(2):217-24. PubMed ID: 23562753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cationic drugs and COVID-19.
    Brenna OV; Torretta S; Pignataro L; Di Berardino F
    Int J Immunopathol Pharmacol; 2020; 34():2058738420966078. PubMed ID: 33045858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinase Inhibitors as Underexplored Antiviral Agents.
    García-Cárceles J; Caballero E; Gil C; Martínez A
    J Med Chem; 2022 Jan; 65(2):935-954. PubMed ID: 33970631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Professor De Clercq and 25 years of international collaboration on antiviral research.
    Colacino JM
    Antivir Chem Chemother; 2013 May; 23(2):57-8. PubMed ID: 22992324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Drug Discovery for Treatment of Virus Diseases.
    Joon S; Singla RK; Shen B
    Adv Exp Med Biol; 2022; 1368():73-93. PubMed ID: 35594021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial overview: antivirals and resistance: advances and challenges ahead.
    Menéndez-Arias L; Richman DD
    Curr Opin Virol; 2014 Oct; 8():iv-vii. PubMed ID: 25155454
    [No Abstract]   [Full Text] [Related]  

  • 17. Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model.
    Everts M; Cihlar T; Bostwick JR; Whitley RJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():155-169. PubMed ID: 27483339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human monoclonal antibodies as candidate therapeutics against emerging viruses.
    Jin Y; Lei C; Hu D; Dimitrov DS; Ying T
    Front Med; 2017 Dec; 11(4):462-470. PubMed ID: 29159596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel antiviral pipeline to treat severe neonatal viral infections.
    Kadambari S; Griffiths PD; Sharland M
    Pediatr Infect Dis J; 2013 Jun; 32(6):682-3. PubMed ID: 23435310
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses.
    Wang X; Zou P; Wu F; Lu L; Jiang S
    Front Med; 2017 Dec; 11(4):449-461. PubMed ID: 29170916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.